Parathyroid Hormone versus Bisphosphonate Treatment on Bone Mineral Density in Osteoporosis Therapy: A Meta-Analysis of Randomized Controlled Trials

Use of Recombinant Human Parathyroid Hormone(1–84) in Patients with Postmenopausal Osteoporosis

(2013) Rüdiger Möricke et al.   CLINICAL DRUG INVESTIGATION

Bone anabolic versus bone anticatabolic treatment of postmenopausal osteoporosis

(2010) George P. Lyritis et al.   Annals of the New York Academy of Sciences

The use of PTH in the treatment of osteoporosis

(2010) Victória Z. Cochenski Borba et al.   Arquivos Brasileiros de Endocrinologia e Metabologia

2010 clinical practice guidelines for the diagnosis and management of osteoporosis in Canada: summary

(2010) A. Papaioannou et al.   CANADIAN MEDICAL ASSOCIATION JOURNAL

Effects of intravenous zoledronic acid plus subcutaneous teriparatide [rhPTH(1-34)] in postmenopausal osteoporosis

(2010) Felicia Cosman et al.   JOURNAL OF BONE AND MINERAL RESEARCH

Effects of Teriparatide, Alendronate, or Both in Women with Postmenopausal Osteoporosis

(2010) Joel S. Finkelstein et al.   JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM

PTH-analogs: Comparable or different?

(2009) H.J.J. Verhaar et al.   ARCHIVES OF GERONTOLOGY AND GERIATRICS

The PRISMA Statement for Reporting Systematic Reviews and Meta-Analyses of Studies That Evaluate Health Care Interventions: Explanation and Elaboration

(2009) Alessandro Liberati et al.   PLOS MEDICINE

Head-to-head comparison of risedronate vs. teriparatide on bone turnover markers in women with postmenopausal osteoporosis: a randomised trial

(2008) A. D. Anastasilakis et al.   INTERNATIONAL JOURNAL OF CLINICAL PRACTICE

Recent developments in the management of postmenopausal osteoporosis with bisphosphonates: enhanced efficacy by enhanced compliance

(2008) S. Boonen et al.   JOURNAL OF INTERNAL MEDICINE